ArticleThe FEBS journal2026
Structural characterization of endogenous microprotein EMBOW reveals an alternative MRT motif for WDR5-interacting site recognition.
Article in The FEBS journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- No Time to Fold: Intrinsically Disordered Microproteins in Action.Biochemistry · 2026Review
- Microproteins in Human Physiology and Pathology.Biochemistry · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
WD repeat-containing protein 5 (WDR5) is a conserved chromatin regulator that engages numerous binding partners via a central arginine-binding pocket known as the WDR5-interacting (WIN) site. Endogenous microprotein binder of WDR5 (EMBOW, also known as SCRIB overlapping open reading frame protein), recently identified as an endogenous WDR5 interactor, lacks the canonical [ACR]-R-[TASCK] WIN motif, and its mode of recognition remains unknown. Here, we present the 1.80 Å crystal structure of WDR5 in complex with an EMBOW-derived peptide. Our structural analysis reveals that EMBOW engages the WIN site through a Met1-Arg2-Thr3 (MRT) triad. The bulky Met1 residue occupies the conserved WIN site pocket, and mutation of Thr3 to valine reduces binding affinity, while N-terminal Gly-Ser insertion preserves binding, indicating a degree of structural tolerance. Binding assays and mutational analysis underscore the functional importance of the MRT triad. Furthermore, structural and biochemical studies of MRT-containing peptides from RNA-binding protein 15 (RBM15) and zinc finger and SCAN domain-containing protein 10 (ZSCAN10) suggest that this motif may serve as an alternative WIN site recognition signature. In summary, our findings define the molecular basis of EMBOW-WDR5 interaction and expand the sequence space compatible with WIN site engagement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.